The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Inclusion Criteria: * 18 ≤ age ≤75, male; * ECOG score of physical condition is 0 \~ 1; * The expected survival time is at least 3 months; * Prostatic adenocarcinoma confirmed by histological or cytological examination, with no indication of neuroendocrine or small-cell characteristics; * The functional level of organs must meet the following requirements (no blood transfusion or hematopoietic growth factor treatment was received within 2 weeks before routine blood screening) : * ANC ≧ 1.5 x 109 / L; * PLT ≧ 80 x 109 / L; * Hb ≧ 90 g/L; * TBIL ≦1.5 x ULN; * ALT and AST≦2.5×ULN; * BUN and Cr ≦1.5 x ULN; * GFR ≧ 60 ml/min / 1.73 m2. * According to the researcher's judgment, it can comply with the experimental scheme; * Volunteer to participate in this clinical trial, understand the study procedures and have signed informed consent. Exclusion Criteria: * 1\. Any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, etc.), except ADT therapy, shall be completed until the washout period of the first drug administration in this study is \<4 weeks; * Plan to receive any other anti-tumor therapy during the study; * As subjects, to participate in other drug clinical trials, the last trial drug administration is less than 4 weeks from the first administration of the drug in this study; * The presence of intracerebral tumor lesions according to imaging diagnosis; * Have a history of epilepsy, or have dise…